

# Erik Fink Eriksen

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/11064973/erik-fink-eriksen-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

52  
papers

6,645  
citations

24  
h-index

57  
g-index

57  
ext. papers

7,467  
ext. citations

6.7  
avg, IF

5.5  
L-index

#	Paper	IF	Citations
52	Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. <i>New England Journal of Medicine</i> , <b>2007</b> , 356, 1809-22	59.2	2094
51	Zoledronic acid and clinical fractures and mortality after hip fracture. <i>New England Journal of Medicine</i> , <b>2007</b> , 357, 1799-809	59.2	1410
50	Cellular mechanisms of bone remodeling. <i>Reviews in Endocrine and Metabolic Disorders</i> , <b>2010</b> , 11, 219-27	10.5	408
49	Effects of Thyroid Hormones on Bone and Mineral Metabolism. <i>Endocrinology and Metabolism Clinics of North America</i> , <b>1990</b> , 19, 35-63	5.5	283
48	Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS. <i>Bone</i> , <b>2017</b> , 105, 11-17	4.7	269
47	Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers. <i>Journal of Bone and Mineral Research</i> , <b>2001</b> , 16, 1575-82	6.3	259
46	Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. <i>Journal of Bone and Mineral Research</i> , <b>2011</b> , 26, 503-11	6.3	256
45	Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis. <i>Journal of Bone and Mineral Research</i> , <b>2006</b> , 21, 855-64	6.3	180
44	Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. <i>Journal of Bone and Mineral Research</i> , <b>2005</b> , 20, 1244-53	6.3	175
43	Polymorphisms in the osteoprotegerin gene are associated with osteoporotic fractures. <i>Journal of Bone and Mineral Research</i> , <b>2002</b> , 17, 1245-55	6.3	139
42	Remodeling and vascular spaces in bone. <i>Journal of Bone and Mineral Research</i> , <b>2007</b> , 22, 1-6	6.3	121
41	Hormone replacement therapy prevents osteoclastic hyperactivity: A histomorphometric study in early postmenopausal women. <i>Journal of Bone and Mineral Research</i> , <b>1999</b> , 14, 1217-21	6.3	112
40	Assessment of bone remodeling using biochemical indicators of type I collagen synthesis and degradation: relation to calcium kinetics. <i>Bone and Mineral</i> , <b>1994</b> , 24, 81-94		103
39	Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. <i>Journal of the American Geriatrics Society</i> , <b>2010</b> , 58, 292-9	5.6	91
38	Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture. <i>Journal of Bone and Mineral Research</i> , <b>2009</b> , 24, 1308-13	6.3	82
37	Osteoporotic fractures are associated with an 86-base pair repeat polymorphism in the interleukin-1--receptor antagonist gene but not with polymorphisms in the interleukin-1beta gene. <i>Journal of Bone and Mineral Research</i> , <b>2000</b> , 15, 402-14	6.3	79
36	A TA repeat polymorphism in the estrogen receptor gene is associated with osteoporotic fractures but polymorphisms in the first exon and intron are not. <i>Journal of Bone and Mineral Research</i> , <b>2000</b> , 15, 2222-30	6.3	79

35	The von Kossa reaction for calcium deposits: silver lactate staining increases sensitivity and reduces background. <i>The Histochemical Journal</i> , <b>1993</b> , 25, 446-51		68
34	Bone marrow lesions: a universal bone response to injury?. <i>Rheumatology International</i> , <b>2012</b> , 32, 575-84	3.6	54
33	Histomorphometric Analysis of Bone in Metabolic Bone Disease. <i>Endocrinology and Metabolism Clinics of North America</i> , <b>1989</b> , 18, 919-954	5.5	49
32	Single unit filter-aided method for fast proteomic analysis of tear fluid. <i>Analytical Biochemistry</i> , <b>2015</b> , 480, 1-5	3.1	36
31	Treatment of osteopenia. <i>Reviews in Endocrine and Metabolic Disorders</i> , <b>2012</b> , 13, 209-23	10.5	29
30	Reduced Bone Material Strength is Associated with Increased Risk and Severity of Osteoporotic Fractures. An Impact Microindentation Study. <i>Calcified Tissue International</i> , <b>2017</b> , 101, 34-42	3.9	28
29	Women with previous stress fractures show reduced bone material strength. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , <b>2016</b> , 87, 626-631	4.3	24
28	High-sensitivity C-reactive protein is an independent risk factor for non-vertebral fractures in women and men: The Tromsø Study. <i>Bone</i> , <b>2015</b> , 72, 65-70	4.7	22
27	Bone metabolism, bone mineral density and low-energy fractures 10 years after Roux-en-Y gastric bypass. <i>Bone</i> , <b>2019</b> , 127, 436-445	4.7	22
26	New developments in the treatment of osteoporosis. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , <b>2013</b> , 92, 620-36	3.8	18
25	High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis - a randomized controlled trial. <i>BMC Neurology</i> , <b>2017</b> , 17, 67	3.1	15
24	Primary hyperparathyroidism: lessons from bone histomorphometry. <i>Journal of Bone and Mineral Research</i> , <b>2002</b> , 17 Suppl 2, N95-7	6.3	15
23	Ultrastructure of human osteoblasts and associated matrix in culture. <i>Apmis</i> , <b>1992</b> , 100, 490-7	3.4	14
22	Relationships of serum 25-hydroxyvitamin D, ionized calcium and parathyroid hormone after obesity surgery. <i>Clinical Endocrinology</i> , <b>2018</b> , 88, 372-379	3.4	13
21	Commentary: Concurrent administration of PTH and antiresorptives: Additive effects or DXA cosmetics. <i>Bone</i> , <b>2016</b> , 86, 139-42	4.7	13
20	Characteristics of glucose metabolism in Nordic and South Asian subjects with type 2 diabetes. <i>PLoS ONE</i> , <b>2013</b> , 8, e83983	3.7	13
19	Changes in Bone Marrow Adipose Tissue One Year After Roux-en-Y Gastric Bypass: A Prospective Cohort Study. <i>Journal of Bone and Mineral Research</i> , <b>2019</b> , 34, 1815-1823	6.3	11
18	Bone mineral density in patients with multiple sclerosis, hereditary ataxia or hereditary spastic paraplegia after at least 10 years of disease - a case control study. <i>BMC Neurology</i> , <b>2016</b> , 16, 252	3.1	9

17	Assessment of erosion depth by lamellar counting. <i>Bone</i> , <b>1993</b> , 14, 443-7	4.7	8
16	Bisphosphonates as a treatment modality in osteoarthritis. <i>Bone</i> , <b>2021</b> , 143, 115352	4.7	8
15	Presence of pyrophosphate in bone from an atypical femoral fracture site: A case report. <i>Bone Reports</i> , <b>2017</b> , 6, 81-86	2.6	7
14	Establishment of a tear protein biomarker panel differentiating between Graves Disease with or without orbitopathy. <i>PLoS ONE</i> , <b>2017</b> , 12, e0175274	3.7	7
13	Osteonecrosis after intranasal injection with bevacizumab in treating hereditary hemorrhagic telangiectasia: A case report. <i>Laryngoscope</i> , <b>2018</b> , 128, 593-596	3.6	6
12	Commentary on sclerostin deficiency is linked to altered bone composition. <i>Journal of Bone and Mineral Research</i> , <b>2014</b> , 29, 2141-3	6.3	3
11	Relationships Between Vitamin D Status and PTH over 5 Years After Roux-en-Y Gastric Bypass: a Longitudinal Cohort Study. <i>Obesity Surgery</i> , <b>2020</b> , 30, 3426-3434	3.7	3
10	Mechanisms of Bone Remodeling <b>2013</b> , 31-45		2
9	Validation of Biochemical Markers of Bone Turnover <b>2006</b> , 583-594		2
8	Effects of anticatabolic and anabolic therapies at the tissue level. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , <b>2006</b> , 4, 177-196	2.5	1
7	Bone changes in metabolic bone disease. <i>Acta Orthopaedica</i> , <b>1995</b> , 66, 195-201		1
6	Response to letter to the editor by Leder et al. regarding commentary "Concurrent administration of PTH and antiresorptives: Additive effects or DXA cosmetics". <i>Bone</i> , <b>2016</b> , 89, 75-76	4.7	1
5	Consensus development statement on osteoporosis. <i>Osteoporosis International</i> , <b>1997</b> , 7, 589	5.3	
4	Anabolics <b>2016</b> , 37-59		
3	The Use of Bone Biopsies in the Diagnosis of Male Osteoporosis <b>2010</b> , 577-588		
2	Parathyroid Hormone: Anabolic Treatment of Osteoporosis 158-177		
1	Osteotropic proteins in bone marrow do not reflect abundance in bone and bone remodeling in obese females. <i>Obesity Medicine</i> , <b>2022</b> , 32, 100408	2.6	